Search results for: Multi-Indication Medicines
Filter search results
OHE at the Health Economists’ Study Group (HESG) Meeting, Manchester 2016
4 January 2016
…multinational trials should report country-specific cost-effectiveness results, yet typically these country specific results are only used to assess the between-location variability. We use value of information (VOI) analysis (assuming a…
An Insurance Framework for Funding New Antibiotics
22 September 2017
A new paper sets out an insurance model as part of a global solution to incentivise R&D for new antibiotics to tackle multi-drug resistance. It offers (i) a reasonable return…
OHE at HESG, AES and PROMs Summer 2018
15 June 2018
…Exploring the Factors That Influence Workforce Participation of People with Multiple Sclerosis: A Discrete Choice Experiment (Goodwin et al) The theme for the 38th edition of the Spanish Health Economics…
Patient Preferences for Diagnostic Tests Aimed at Managing Antimicrobial Resistance
7 October 2019
…This work was funded by ‘Tackling AMR – A Cross Council Initiative’ (grant ref: MR/N014316/1). Mott, D.J., Hampson, G., Llewelyn, M.J., Mestre-Ferrandiz, J. and Hopkins, M.M., 2019. A Multinational…
Opportunity Cost in Health Care: a Favourite Research Topic for OHE
23 November 2021
…so simple. We seldom have a clear understanding of the next best alternative for expenditure in health care. The challenge operates on multiple levels. For starters, there is often a…
Let’s talk about (health) inequalities
1 April 2022
…Healthy Lives’. A cross-sector approach to reduce health inequalities is essential, due to the multiple links between health and individual experience, especially educational attainment, living conditions, and access to services….
Improving the Measurement of Valued Output in Primary Care in England
1 August 2022
…when there are multiple types of outputs, and there is no obvious way to combine them into a single aggregate figure. For efficiency research to be insightful, we argue that…
Challenges and Opportunities for Improving Benefit-Risk Assessment of Pharmaceuticals from an Economic Perspective
1 August 2008
…evaluate drug benefit and risk. Four methods were presented and discussed: health outcomes modelling using quality-adjusted life years, incremental net health benefit, stated benefit-risk preferences, and multi-criteria decision analysis. Each…
The New Global Economics of Vaccines: Will the Scientific Potential Be Realised?
1 January 2007
…vaccines. Some of these are emerging from GSK and the other two remaining large multinational producers; however, there are also new entrants into the vaccine market, including a couple of…